Jenkem Technology (688356.SH): The three-component LNP developed in collaboration with Cansino Biologics Inc. can be licensed to other companies.

Jenkem Technology (688356.SH) stated on the investor interaction platform on July 16 that the three-component LNP developed in cooperation with Cansino Biologics Inc. can be licensed to other companies.

Gelonghui FinanceJul 16 03:35 ET

Cansinobio received shareholding of 0.02 million H shares from its controlling shareholder, Yu Xuefeng.

Cansinobio (06185) issued an announcement on July 9, 2024, stating that the company received notice from XUEFENG YU, one of its controlling shareholders and chairman and CEO, that he has increased his shareholding by 0.02 million H shares, accounting for 0.01% of the company's total share capital (as of July 9, 2024, the company's total share capital was 0.247 billion shares, including 0.133 billion H shares and 0.115 billion A shares). Prior to this shareholding increase, XUEFENG YU directly held 11.5902 million H shares, and after the increase, he directly holds 11.6102 million H shares.

新浪港股Jul 11 19:38 ET

Cansino Biologics Inc. (listed in Hong Kong Stock Exchange with ticker 688185.SH): Director and CEO Yu Xuefeng increases shareholding by 0.02 million H shares.

On July 11th, Gelunhui reported that Cansino Biologics Inc. (688185.SH) announced that on July 9th, 2024, it received notification from XUEFENG YU, one of its controlling shareholders and chairman and general manager, that he had increased his holdings of the company's H shares by 20,000 shares, accounting for approximately 0.01% of the company's total share capital (as of July 9th, 2024, the company's total share capital was 247,449,899 shares, of which 132,670,900 shares were H shares and 114,778,999 shares were A shares). Prior to this shareholding, XUEFENG YU directly held 11,590 shares of the company.

Gelonghui FinanceJul 11 06:35 ET

Cansinobio (06185): Li Zhicheng was elected as a non-executive director.

Cansinobio (06185) announced in a statement on the Zhītōng Cáijīng APP that Mr. Li Zhicheng was elected as a non-executive director of the third board of directors at the annual shareholder meeting.

Zhitong FinanceJun 27 10:05 ET

Cansino Biologics' Senior Management to Boost Stakeholding

MT NewswiresJun 24 08:05 ET

HK stock surged: CansinoBIO (06185) rose by nearly 4%. The controlling shareholder and executive director plan to increase their shareholding in the company.

Zhītōng Cáijīng APP learned that Cansinobio (06185) rose nearly 4%. As of the time of publication, it has risen 3.74% to HKD 20.75, with a turnover of HKD 7.7283 million. In recent news, Cansinobio announced that its board of directors has received Dr. Xuefeng Yu (Chairman of the Board of the company, Chief Executive Officer, General Manager and one of the controlling shareholders, "Dr. Yu"), Dr. ShouBai Chao (Executive Director, Chief Operating Officer and Deputy General Manager of the company, "Dr. Chao"), and Dr. Zhu Tao (Chief Scientific Officer, Deputy General Manager and one of the controlling shareholders of the company, "Dr. Zhu").

Zhitong FinanceJun 23 21:53 ET